# Reyvow (lasmiditan succinate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lasmiditan

> The FDA approved Reyvow (lasmiditan succinate), sponsored by ELI LILLY & Co (LLY), on October 11, 2019.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Reyvow (lasmiditan succinate) |
| Codes | LY573144 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Migraine](https://sec-api.dev/indications/migraine) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 11, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211280 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191011, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product REYVOW (LASMIDITAN SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211280%22

### November 12, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04396236 (A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-02." https://clinicaltrials.gov/study/NCT04396236

### December 4, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04396574 (A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-25." https://clinicaltrials.gov/study/NCT04396574

## Same indication

- [Qulipta (atogepant)](https://sec-api.dev/pdufa/atogepant) (ABBV)
- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab) (AMGN)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab) (TEVA)
- [MEDI0618](https://sec-api.dev/pdufa/medi0618) (ABBV)
- [Nurtec Odt (rimegepant sulfate)](https://sec-api.dev/pdufa/rimegepant) (PFE)
- [Ubrelvy (ubrogepant)](https://sec-api.dev/pdufa/ubrogepant) (ABBV)
- [Zavzpret ® (zavegepant)](https://sec-api.dev/pdufa/zavegepant) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lasmiditan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Reyvow (lasmiditan succinate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lasmiditan

```bibtex
@misc{secapidev_pdufa_lasmiditan_20261116,
  title        = {Reyvow (lasmiditan succinate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lasmiditan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lasmiditan_20261116","title":"Reyvow (lasmiditan succinate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lasmiditan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
